Proactive Investors - Run By Investors For Investors

ImmuPharma cancer programme talks continue

Conversations with Incanthera are continuing even though an extended period of exclusivity has lapsed
cancer cells
The company is keen to find a partner for its Nucant cancer programme

ImmuPharma PLC (LON:IMM) said a period of exclusivity has run out between it and Incanthera Limited, which allows the ImmuPharma to discuss collaborations with other potential partners for its Nucant cancer programme.

“Notwithstanding the expiry of the exclusivity period, discussions with Incanthera are continuing in good faith for broader collaboration,” the AIM-listed life sciences group told investors.

READ: ImmuPharma says article shines light on potential of peptide subsidiary

“There can be no guarantee that any agreement will be reached with Incanthera on a broader collaboration.”

An outline deal was inked last September, at which point ImmuPharma took a £2mln stake in Incanthera. The deadline for a definitive agreement was extended from the end of December to the end of March.

View full IMM profile View Profile

ImmuPharma PLC Timeline

Related Articles

A doctor's stethoscope and a marijuana plant
February 22 2019
With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals
September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
February 22 2019
The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use